Assistant Professor, Medicine, Tufts Medical Center

Pediatric Hematology & Oncology

Giannoula Klement practices Pediatric Hematology & Oncology. She researched medicine at McMaster University School of Medicine. Dr. Giannoula L. Klement is a published doctor. She published 38 publications, including: 'An oral ivermectin regimen that eradicates pinworms (Syphacia spp.) in laboratory rats and mice.'

Publications

---

• The toxicity of anti-VEGF agents when coupled with standard chemotherapeutics.
• Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.
• Interdisciplinary management of congenital infiltrating lipomatosis.
• Center of cancer systems biology second annual workshop--tumor metronomics: timing and dose level dynamics.
• Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet ...
• Isolation and proteomic analysis of platelets by SELDI-TOF MS.
• Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World?
• The role of angiogenesis in the transformation of plexiform neurofibroma into malignant peripheral nerve sheath tumors in children with neurofibromatosis type 1.
• Normal ranges of angiogenesis regulatory proteins in human platelets.
• Platelets actively sequester angiogenesis regulators.
• Pharmacological treatment of a diffuse arteriovenous malformation of the upper extremity in a child.
• Megakaryocyte-derived microparticles: direct visualization and distinction from platelet-derived microparticles.
• Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released.
• Platelet-associated PF-4 as a biomarker of early tumor growth.
• Tumors stimulate platelet delivery of angiogenic factors in vivo: an unexpected benefit.
• Successful antiangiogenic therapy for neuroblastoma with thalidomide.
• Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts.
• Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts.
• Differences in vasculature between pilocytic and anaplastic astrocytomas of childhood.
• MicroCT scanner performance and considerations for vascular specimen imaging.
• The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells.
• Targeting cyclooxygenase-2 reduces overt toxicity toward low-dose vinblastine and extends survival of juvenile mice with Friend disease.
• A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice.
• Cutaneovisceral angiomatosis with thrombocytopenia.
• A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer.
• Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry.
• Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease.
• Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.
• ''Accidental'' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
• Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.
• Multicellular gastric cancer spheroids recapitulate growth pattern and differentiation phenotype of human gastric carcinomas.
• Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic.
• Oncogenes and angiogenesis: signaling three-dimensional tumor growth.
• Impact of oncogenes and tumor suppressor genes on deregulation of hemostasis and angiogenesis in cancer.
• Single residue (K332A) substitution in Kir6.2 abolishes the stimulatory effect of long-chain acyl-CoA esters: indications for a long-chain acyl-CoA ester binding motif.
• Hyperthermia inhibits platelet hemostatic functions and selectively regulates the release of alpha-granule proteins.
• An oral ivermectin regimen that eradicates pinworms (Syphacia spp.) in laboratory rats and mice.

Schools

---

• McMaster University Faculty of Health Sciences

• Hospital For Sick Children

• Dana Farber Cancer Institution

• Sunnybrook Health Centre

Doctors Specialties

---

• Pediatrics
• Pediatric Hematology
• Oncology

Accepted Insurances

---

Education

---

• McMaster University School of Medicine

Hospital

---

• Tufts Medical Center

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Veronica Dussel, MD This Doctor is OpenDoctor Recommended.
	Dr. Erica B. Esrick, MD This Doctor is OpenDoctor Recommended.
	Dr. Susan N. Chi, MD This Doctor is OpenDoctor Recommended.
	Dr. Jennifer S. Whangbo, MD This Doctor is OpenDoctor Recommended.
	Dr. Katherine E. Nelson, MD This Doctor is OpenDoctor Recommended.
	Dr. Timothy W. Menza, MD This Doctor is OpenDoctor Recommended.
	Dr. Katharine B. Herrick, MD This Doctor is OpenDoctor Recommended.
	Dr. Rima A. Rachid, MD This Doctor is OpenDoctor Recommended.
	Dr. Margot L. Newburger, MD
	Dr. Junne Kamihara, MD This Doctor is OpenDoctor Recommended.
	Dr. Nancy G. Geis, MD This Doctor is OpenDoctor Recommended.
	Dr. Rafael Correa, MD
	Dr. Aaron S. Bernstein, MD
	Dr. Thomas J. Schuch, MD This Doctor is OpenDoctor Recommended.
	Dr. Nicolas J. Llosa, MD This Doctor is OpenDoctor Recommended.
	Dr. Erlinda R. Ulloa, MD
	Dr. Cynthia S. Kretschmar, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog